1991 Fiscal Year Final Research Report Summary
Immunotherapy of lung cancer using biotechnological methods.
| Project/Area Number |
01480338
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
KIMURA Hideki Chiba Univ., 医学部, 講師 (10161572)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YUSA Toshikazu Chiba Univ., 医学部, 助手 (70230620)
BABA Masayuki Chiba Univ., 医学部, 助手 (00143305)
SHIBA Mitsutoshi Chiba Univ., 医学部, 助手 (20162620)
FUJISAWA Takehiko Chiba Univ., 医学部, 助教授 (80110328)
YAMAGUCHI Yutaka Chiba Univ., 医学部, 教授 (80009448)
|
|---|
| Project Period (FY) |
1989 – 1991
|
| Keywords | Lung Cancer / Immunotherapy / LAK cell / IL-2 / Adjuvant treatment |
|---|
| Research Abstract |
A controlled, randomized study has been conducted to assess the efficacy of adoptive immunotherapy with Interleukin 2(IL2)and lymphokine activated killer cells(LAK cells)combined with chemotherapy or radiotherapy for advanced non-small cell lung cancer(NSCLC)patients. Out of 403 NSCLC patients who received resection of primary tumors from Jan. 1985 to Dec. 1990 in our hospital, a total of 106 patients with relatively curative and non-curative resection, were entered into a randomized controlled trial of postoperative adjuvant immunotherapy. The former group(n=36)was divided into three groups ; a)Chemotherapy(CDDP+VDS)group(n=13), b)Chemoimmunotherapy(CDDP+VDS+IL2+LAK cells)group(n=12), and c)control group(n=ll). The latter(noncurative)group(n=68)was randomized into d)immunotherapy(chemo/radiotherapy+IL2+LAK cells)group(n=33)and e)control(chemo/radiotherapy alone)group(n=35).
The overall 4 year survival rates of immunotherapy(b+d)and control(a+c+e)groups were 52.4% and 28.3% respectively and the difference was significant(p<0.01)with generalized Wilcoxon test. In the relative curative group, the 4 year survival rates of a), b), and c)groups were 34.2%, 70.9% and 34.1% respectively. In the non-curative group, those of d)and e)groups were 43.1% and 29.3%(p<0.05). From this study, it it suggested that adoptive immunotherapy with IL2 and LAK cells is effective as a postoperative adjuvant immunotherapy for advanced NSCLC patients.
|
